NCI Trials Mirdametinib and Sirolimus in RAS Mutated Relapsed Refractory Multiple Myeloma
A clinical trial is underway to evaluate the safety and efficacy of mirdametinib and sirolimus in patients with RAS mutated relapsed refractory multiple myeloma.
Phase III
Multiple Myeloma therapies
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing clinical trial evaluating mirdametinib and sirolimus for RAS mutated relapsed refractory multiple myeloma could significantly enhance treatment options in a challenging patient population. Successful outcomes may shift competitive dynamics in the multiple myeloma market and inform future development strategies for pharma companies.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include safety data from the first part of the trial and efficacy results from the second part, particularly in relation to RAS mutation status.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.